arginine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1549 74-79-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • l-arginine
  • L-Arg
  • arginine
  • arginine hydrochloride
  • arginine HCl
An essential amino acid that is physiologically active in the L-form.
  • Molecular weight: 174.20
  • Formula: C6H14N4O2
  • CLOGP: -3.04
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 5
  • TPSA: 125.22
  • ALOGS: -1.88
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 68 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 28, 1973 FDA PHARMACIA AND UPJOHN
June 23, 2021 PMDA FUJIFILM TOYAMA CHEMICAL Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 58.95 25.11 15 826 6612 50597671
Hyperammonaemic crisis 58.04 25.11 7 834 32 50604251
Infantile apnoea 42.55 25.11 8 833 865 50603418
Selective eating disorder 36.64 25.11 8 833 1824 50602459
Hyperammonaemia 33.80 25.11 9 832 4715 50599568
Cerebral haemorrhage 31.28 25.11 13 828 27039 50577244
Ammonia increased 29.96 25.11 8 833 4233 50600050
Device related sepsis 26.67 25.11 7 834 3468 50600815
Right ventricular failure 26.66 25.11 10 831 15883 50588400

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 84.79 26.41 11 955 45 29573516
Haematuria 78.67 26.41 35 931 44104 29529457
Blindness cortical 57.95 26.41 10 956 335 29573226

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 108.16 22.29 14 1474 85 64497159
Haematuria 73.13 22.29 33 1455 60438 64436806
Blindness cortical 52.84 22.29 10 1478 803 64496441
Hyperammonaemia 39.82 22.29 13 1475 9891 64487353
Ammonia increased 35.67 22.29 11 1477 6966 64490278
Blood osmolarity decreased 26.22 22.29 6 1482 1212 64496032

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B05XB01 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTION ADDITIVES
Amino acids
ATC V03AF11 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:50733 Dietary Supplement
CHEBI has role CHEBI:59163 biological marker
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:78675 fundamental metabolites
CHEBI has role CHEBI:75772 S. cerevisiae metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Renal radiation exposure from Lutetium (177Lu) oxodotreotide indication 218190002
Diagnostic Test for Growth Hormone Secretion indication
Renal tubular acidosis contraindication 1776003 DOID:14219
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Constipation contraindication 14760008 DOID:2089
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Metabolic acidosis contraindication 59455009
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hb SS disease contraindication 127040003 DOID:10923
Osteolysis contraindication 203522001
Myocardial infarction in recovery phase contraindication 418044006
Allergic Reactions contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.97 acidic
pKa2 11.72 Basic
pKa3 8.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Nitric oxide synthase, inducible Enzyme Kd 5.15 CHEMBL
G-protein coupled receptor family C group 6 member A GPCR AGONIST EC50 4.40 IUPHAR

External reference:

IDSource
4018668 VUID
N0000146979 NUI
D02982 KEGG_DRUG
1119-34-2 SECONDARY_CAS_RN
4018668 VANDF
4019067 VANDF
C0003765 UMLSCUI
CHEBI:29016 CHEBI
ARG PDB_CHEM_ID
CHEMBL1485 ChEMBL_ID
CHEMBL1200381 ChEMBL_ID
D001120 MESH_DESCRIPTOR_UI
DB00125 DRUGBANK_ID
721 IUPHAR_LIGAND_ID
1711 INN_ID
94ZLA3W45F UNII
6322 PUBCHEM_CID
1091 RXNORM
14778 MMSL
206 MMSL
40033 MMSL
4219 MMSL
7609 MMSL
7610 MMSL
d00578 MMSL
000926 NDDF
005095 NDDF
52625008 SNOMEDCT_US
63676001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
R-Gene HUMAN PRESCRIPTION DRUG LABEL 1 0009-0436 INJECTION, SOLUTION 10 g INTRAVENOUS NDA 17 sections
R-Gene HUMAN PRESCRIPTION DRUG LABEL 1 0009-0436 INJECTION, SOLUTION 10 g INTRAVENOUS NDA 17 sections
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.29 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 1.20 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 1.20 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 1.47 g INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 1.47 g INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 1.47 g INTRAVENOUS ANDA 20 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9010 INJECTION, SOLUTION 0.95 g INTRAVENOUS NDA 24 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9011 INJECTION, SOLUTION 0.95 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 1.20 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.73 g INTRAVENOUS NDA 23 sections
HepatAmine HUMAN PRESCRIPTION DRUG LABEL 16 0264-9371 INJECTION, SOLUTION 0.60 g INTRAVENOUS NDA 23 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 690 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 920 mg INTRAVENOUS NDA 20 sections
ProSol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0499 INJECTION, SOLUTION 1.96 g INTRAVENOUS NDA 21 sections
Clinisol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0502 INJECTION, SOLUTION 1.47 g INTRAVENOUS ANDA 18 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 1.15 g INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1101 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 489 mg INTRAVENOUS NDA 20 sections